+

WO2003035106A1 - Procedes et compositions servant a induire une reponse immune - Google Patents

Procedes et compositions servant a induire une reponse immune Download PDF

Info

Publication number
WO2003035106A1
WO2003035106A1 PCT/US2001/042852 US0142852W WO03035106A1 WO 2003035106 A1 WO2003035106 A1 WO 2003035106A1 US 0142852 W US0142852 W US 0142852W WO 03035106 A1 WO03035106 A1 WO 03035106A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
cell
cells
chemotaxin
apc
Prior art date
Application number
PCT/US2001/042852
Other languages
English (en)
Inventor
Thomas J. Schall
Dale Talbot
Robert Berkovitz
Wei Zheng
Howard Maureen
Brett Premack
Original Assignee
Chemocentryx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx filed Critical Chemocentryx
Priority to PCT/US2001/042852 priority Critical patent/WO2003035106A1/fr
Publication of WO2003035106A1 publication Critical patent/WO2003035106A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • compositions and methods for inducing or enhancing an immune response to an antigen are provided.
  • the compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies for therapeutic or diagnostic use).
  • BACKGROUND Immunization is a widely used method to elicit an immune response to an antigen for prophylactic purposes. For example, by administering a harmless form of an antigen from a pathogen, such as an attenuated virus, the production of antibodies and stimulation of immune cells specific for the harmful form of the pathogen occurs.
  • a pathogen such as an attenuated virus
  • present immunization methods are not effective for all antigens.
  • Improved methods and reagents for vaccination are desired by the medical community.
  • the invention provides a method for inducing an immune response to an antigen in a subject by administering a composition containing an antigen-presenting cell chemotaxin (APC chemotaxin).
  • APC chemotaxin is chemotactic for dendritic cells.
  • the APC chemotaxin is chemotactic for immature dendritic cells but is not chemotactic for one or more of mature dendritic cells, neutrophils, T-lymphocytes, monocytes, or eosinophils.
  • the composition contains at least one chemokine polypeptide, or at least two different chemokine polypeptides.
  • the APC chemotaxin is a chemokine polypeptide, such as a naturally occurring chemokine, or variant.
  • the invention provides a method for inducing an immune response in a subject comprising administering a composition containing a chemokine selected hMIPl ⁇ , hMIPl ⁇ (70aa), mMIP-1 ⁇ , hRANTES, hMET-RANTES, mRANTES, hHCC-1, hMPIF-1, hMPIF-1 (22-137), hMPIF-1 (46-137), hMIP-l ⁇ , hMCP-4, mMCP-5, mMARC, mEotaxin, mMCP-l(JE), mTECK, mMIP-2, mBLC, hLeukotactin, mMIG, mMIP-l ⁇ .
  • chemokine is mClO, mMDC, hMIP-l ⁇ , mMIP-l ⁇ , hMCP-2, hMCP-3, vMIP-1, liMIP- 3 ⁇ , and hMIP-3 ⁇ .
  • the invention provides a method for inducing an immune response in a subject comprising administering a composition containing a chimeric polypeptide comprising a sequence with at least 10 contiguous residues from each of at least two different naturally occurring chemokines.
  • At least one or at least two of the chemokines is selected from hMIPl ⁇ , hMIPl ⁇ (70aa), mMIP-1 ⁇ , li ANTES, hMET-RANTES, mRANTES, hHCC-1, hMPIF-1, hMPIF-1 (22-137), hMPIF-1 (46-137), hMIP-l ⁇ , hMCP-4, mMCP-5, mMARC, mEotaxin, mMCP- 1 (JE), mTECK, mMIP-2, mBLC, hLeukotactin, mMIG, mMIP-1 ⁇ .
  • hMCP-2 hMCP- 3, vMJP-1, hMIP-3 ⁇ , hMIP-3 ⁇ , mClO, mMDC, hMIP-l ⁇ , vMCK-2, and/or mMff-l ⁇ .
  • the invention provides a method for inducing an immune response in a subject comprising administering a composition containing an antigen- presenting cell chemotaxin is encoded by polynucleotide produced by in vitro recombination of polynucleotides encoding at least two different naturally occurring chemokines, e.g., selected from hMIPl ⁇ , hMIPl ⁇ (70aa), mMIP-1 ⁇ , hRANTES, hMET-RANTES, mRANTES, hHCC-1, hMPIF-1, hMPIF-1 (22-137), hMPIF-1 (46- 137), hMJP-l ⁇ , hMCP-4, mMCP-5, mMARC, mEotaxin, mMCP-l(JE), mTECK, mMIP-2, mBLC, hLeukotactin, mMIG, mMIP-l ⁇ .
  • chemokines e.g.,
  • the method further includes administering an antigen, e.g. an immunogen, to induce an immune response to that antigen.
  • an antigen e.g. an immunogen
  • the composition and the immunogen may be administered (e.g., by injection) at the same time, for example, by co-injection of a composition that contains the immunogen and the APC chemotaxin.
  • the immunogen is administered to the subject after the composition is administered.
  • the immunogen is a polypeptide from a pathogen or a tumor antigen.
  • composition is administered into or near a solid tumor.
  • APC chemotaxin or the immunogen is administered into or near a solid tumor.
  • composition is administered as a polynucleotide (i.e., encoding a APC chemotaxin polypeptide or immunogen polypeptide).
  • the composition is administered to stimulate the innate immune response of the subject.
  • compositions such as a composition containing a substantially purified APC chemotaxin and a pharmaceutically acceptable excipient.
  • the APC chemotaxin is chemotactic for immature dendritic cells and is not chemotactic for at least one of neutrophils, T cells, B cells, monocytes, and eosinophils.
  • the composition contains more than one substantially purified APC chemotaxin. In one embodiment, the compositions
  • vaccine compositions maybe administered to a subject to immunize the subject against an antigen (e.g., immunogen).
  • an antigen e.g., immunogen
  • the invention further provides the use of an APC chemotaxin disclosed herein, and optionally, a specified antigen, in the formulation of a medicament for inducing an immune response to the specified antigen.
  • the invention further provides a method of formulating a composition capable of inducing an immune response to a specified antigen in a subject by identifying a polypeptide having the activity of an antigen-presenting cell chemotaxin (APC chemotaxin) and combining the polypeptide with the antigen, and optionally with a pharmaceutically acceptable excipient.
  • APC chemotaxin antigen-presenting cell chemotaxin
  • the invention provides compositions comprising polypeptides having an activity of an APC chemotaxin, and an antigen.
  • the invention provides a vaccine comprised of at least one APC chemotaxin, at least one antigen, and at least one adjuvant.
  • the invention provides methods for eliciting an immune response in a subject, comprising administering a vaccine comprising at least one APC chemotaxin, at least one antigen, and at least one adjuvant wherein said vaccine elicits an immune response to the at least one antigen.
  • the adjuvant may be covalently bound to a multivalent carrier.
  • the invention further provides method of enhancing immune responses to a vaccine comprising administering an APC chemotaxin with the vaccine.
  • the APC chemotaxin may be administered via a sustained-release composition.
  • the invention provides pharmaceutical compositions comprising at least one APC chemotaxin and a vaccine, wherein the composition enhances an immune response to the vaccine.
  • APC chemotaxin may be incorporated into a sustained release pharmaceutical composition.
  • kits that comprise pharmaceutical compositions comprising an APC chemotaxin and a pharmaceutically acceptable carrier, and a pharmaceutical carrier comprising a vaccine.
  • APC chemotaxin may be incorporated into a sustained release pharmaceutical composition.
  • the invention provides immunogenic compositions comprising cells that exogenously express an APC chemotaxin.
  • the cells may be allogeneic, especially cancer cells, preferably from the same tissue type (MHC molecules) as that of the cells in a subject, to which the composition is administered.
  • MHC molecules tissue type
  • These compositions in some cases comprise tumor-associated antigens.
  • immunogenic compositions also comprise a first population of cells comprising at least one autologous tumor cell, and a second population of cells comprising at least one allogenic cell exogenously expressing an APC chemotaxin.
  • the tumor and allogenic cells can be made quiescent to inhibit further cell proliferation.
  • Figure 1 shows developmental pathways of dendritic cells.
  • Figure 2 shows the sequence of exemplary chimeric chemokines.
  • Polynucleotide refers to a deoxyribonucleotide (DNA) or ribonucleotide (RNA) in either single- or double-stranded form, and encompasses known analogs of natural nucleotides that can function in a manner similar to the naturally occurring nucleotides.
  • polynucleotide encoding refers to a nucleic acid sequence that directs the expression of a specific protein or peptide.
  • the nucleic acid sequences include both the DNA sequence that is transcribed into RNA and the RNA sequence that is translated into the protein.
  • the nucleic acid sequence includes both the full-length nucleic acid sequence as well as non-full length sequences derived from the full-length sequence.
  • a "subject” is a mammal such as human patient or volunteer, an animal such as a non-human primate, rat, mouse, rodent, rabbit, and the like, an agriculturally important mammal including without limitation, a goat, pig, cow, sheep, horse, horse, pigs, minks, and foxes and the like, and pets such as dogs, cats, and the like.
  • Control sequences are DNA sequences that enable the expression of an operably-linked coding sequence in a particular host organism.
  • Prokaryotic control sequences include promoters, operator sequences, and ribosome binding sites.
  • Eukaryotic cells utilize promoters, polyadenylation signals, and enhancers. Operably-linked
  • Nucleic acid is operably-linked when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably- linked to a coding sequence if it affects the transcription of the sequence, or a ribosome-binding site is operably-linked to a coding sequence if positioned to facilitate translation.
  • "operably-linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by conventional recombinant DNA methods. Isolated nucleic acids
  • An isolated nucleic acid molecule is purified from the setting in which it is found in nature and is separated from at least one contaminant nucleic acid molecule.
  • Isolated APC chemotaxin polynucleotides are distinguished from the specific APC chemotaxin polynucleotide, as it exists in cells.
  • an isolated APC chemotaxin polynucleotide includes APC chemotaxin polynucleotides contained in cells that ordinarily express the APC chemotaxin polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
  • Purified polypeptide An "isolated” or “purified” polypeptide, protein or biologically active fragment is separated and/or recovered from a component of its natural environment.
  • the polypeptide will be purified (1) to obtain at least 15 residues of N-terminal or internal arnino acid sequence using a sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or silver stain.
  • Isolated polypeptides include those expressed heterologously in genetically engineered cells or expressed in vitro since at least one component of the APC chemotaxin polypeptide natural environment will not be present. Ordinarily, isolated polypeptides are prepared by at least one purification step.
  • Contaminant components include materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous materials.
  • the polypeptide is purified to a sufficient degree to obtain at least 15 residues of N- terminal or internal amino acid sequence.
  • An isolated, recombinantly-produced APC chemotaxin polypeptide or biologically active portion is preferably substantially free of culture medium, i.e., culture medium represents less than 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the APC chemotaxin polypeptide preparation.
  • culture medium represents less than 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the APC chemotaxin polypeptide preparation.
  • contaminants include cell debris, culture media, and substances used and produced during in vitro synthesis of APC chemotaxin polypeptide.
  • An active e.g., APC chemotaxin polypeptide or, e.g., APC chemotaxin polypeptide fragment retains a biological and/or an immunological activity similar, but not necessarily identical, to an activity of a naturally-occuring (wild-type) APC chemotaxin polypeptide.
  • Immunological activity in the context of this immediate discussion of the polypeptide per se, and not an actual biological role for APC chemotaxin in eliciting or enhancing an immune response, refers to the ability to be bound by a specific antibody against an antigenic epitope possessed by a native APC chemotaxin polypeptide; biological activity refers to a function, either inhibitory or stimulatory, caused by a native APC chemotaxin.
  • a biological activity of APC chemotaxin polypeptide includes, for example, chemotaxis or enhancing or aiding in the eliciting of an immune response.
  • a particular biological assay (see Examples), with or without dose dependency, can be used to determine APC chemotaxin activity.
  • a nucleic acid fragment encoding a biologically-active portion of APC chemotaxin can be prepared by isolating a polynucleotide sequence that encodes a polypeptide having an APC chemotaxin biological activity, expressing the encoded portion of APC chemotaxin (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of APC chemotaxin polypeptide.
  • Immunological activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native APC chemotaxin polypeptide; biological activity refers to a function, either inhibitory or stimulatory, caused by a native APC chemotaxin polypeptide.
  • an APC chemotaxin polypeptide variant that preserves APC chemotaxin polypeptide-like function and includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further includes the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence.
  • Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.
  • APC chemotaxin polypeptide variant means an active APC chemotaxin polypeptide having at least: (1) about 70% amino acid sequence identity with a full- length native sequence APC chemotaxin polypeptide sequence, (2) an APC chemotaxin polypeptide sequence lacking the signal peptide, (3) an extracellular domain of an APC chemotaxin polypeptide polypeptide, with or without the signal peptide, or (4) any other fragment of a full-length APC chemotaxin polypeptide sequence.
  • APC chemotaxin polypeptide variants include APC chemotaxin polypeptide polypeptides wherein one or more amino acid residues are added or deleted at the N- or C- terminus of the full-length native amino acid sequence.
  • An APC chemotaxin polypeptide variant will have at least about 70% amino acid sequence identity, preferably at least about 71% amino acid sequence identity, more preferably at least about 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% amino acid sequence identity and most preferably at least about 99%> amino acid sequence identity with a full-length native sequence APC chemotaxin polypeptide sequence.
  • An APC chemotaxin polypeptide variant may have a sequence lacking the signal peptide, an extracellular domain of an APC chemotaxin polypeptide polypeptide, with or without the signal peptide, or any other fragment of a full-length APC chemotaxin polypeptide sequence.
  • APC chemotaxin variant polypeptides are at least about 10 amino acids in length, often at least about 20 amino acids in length, more often at least about 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 300 amino acids in length, or more.
  • Percent (%) amino acid sequence identity is defined as the percentage of amino acid residues that are identical with amino acid residues in an APC chemotaxin polypeptide sequence in a candidate sequence when the two sequences are aligned. To determine % amino acid identity, sequences are aligned and if necessary, gaps are introduced to achieve the maximum % sequence identity; conservative substitutions are not considered as part of the sequence identity. Optimal alignment of sequences for comparison can be conducted, e.g. , by the local homology algorithm of Smith & Waterman, 1981, Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman & Wunsch, 1970, J. Mol. Biol.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B can be calculated as:
  • X is the number of amino acid residues scored as identical matches by the sequence alignment program's or algorithm's alignment of A and B and
  • Y is the total number of amino acid residues in B.
  • the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.
  • BLAST algorithm One example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al, 1990, J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology
  • HSPs high scoring sequence pairs
  • Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • polypeptides and fragments of interest can be produced by any method well known in the art, such as by expression via vectors such as bacteria, viruses and eukaryotic cells, h addition, in vitro synthesis, such as peptide synthesis, may be also used.
  • in vitro synthesis such as peptide synthesis
  • a cell sample or cell population is "substantially pure” or “substantially purified” if at least about 75%>, preferably at least about 85%, often at least about 90%, at least about 95% or more of the total cells in the sample are of a defined type (e.g., in a substantially pure preparation of dendritic cells, at least about, e.g., 95%o of the total number of cells are dendritic cells, while in a substantially pure preparation of immature dendritic cells, at least about, e.g., 95% of the total number of cells are immature dendritic cells.
  • An allogeneic cell means a cell that is derived from individuals of the same species that is sufficiently unlike genetically to interact antigenically.
  • An autologous cell means a cell that occurs normally in a tissue or body structure. Such a cell refers to a cell in which the donor and recipient of the cell are the same individual.
  • the method of the invention involves administering a composition that contains an agent that is chemotactic for dendritic cells (DCs) and/or macrophages (together referred to as "antigen-presenting cells” or “APCs").
  • DCs dendritic cells
  • APCs antigen-presenting cells
  • the chemotactic agent is sometimes referred to as a "APC chemotaxin,” and the composition containing the APC chemotaxin (which may contain excipients or other components) is sometimes referred to herein as “the chemotactic composition” or “the composition.”
  • the APC chemotaxin is specifically chemotactic for specified cell types (e.g., dendritic cells) or cell developmental stages (e.g., immature dendritic cells).
  • the agent while chemotactic for some cells, is not chemotactic for certain cell-types (e.g., neutrophils) or cell developmental stages (e.g., mature dendritic cells). Chemotaxis is determined using one or more of the assays described herein.
  • the methods of the invention involve administration of an antigen, in addition to the chemotactic composition.
  • the chemotactic composition and an antigen are administered to the same physical site in the subject.
  • the antigen maybe combined with the chemotactic composition, and the mixture administered (e.g., injected) together.
  • the composition and the antigen are administered separately to the same area of the subject (e.g., injected to the same site, applied topically to the same site, and the like).
  • the composition and antigen are administered at different times.
  • the APC chemotaxin(s) promote(s) an immune reaction to the antigen by recruiting APCs to areas of antigen contact. Antigens are taken up by APCs and partially degraded. Subsequently, a fraction of the degraded antigen is presented with MHC class I or JJ molecules on the surface of the APC. Such cells stimulate proliferation of either cytotoxic T cells or helper T cells, or the production of antibody by B-cells.
  • the chemotactic composition is administered without an accompanying antigen (e.g.
  • injection into a solid tumor to elicit an immune response to cancer cells or injection near, e.g., within 2 cm, of a solid tumor).
  • the APC chemotaxin(s) promote(s) an immune reaction to the endogenous (e.g., tumor) antigen by recruiting APCs to areas of antigen contact.
  • the invention provides, new methods and reagents useful for therapeutic and prophylactic immunization (i.e., the deliberate provocation, enhancement or intensification, of an adaptive immune response).
  • therapeutic and prophylactic immunization i.e., the deliberate provocation, enhancement or intensification, of an adaptive immune response.
  • Particular advantages expected over prior immunization methods include: an accelerated immune response in a host following administration of antigen, a more effective response to administration of, or exposure to, very small quantities of an antigen (e.g., toxin or pathogen) due to increased antigen uptake by APCs, and more effective anti-tumor therapies (e.g. , due to enhanced tumor antigen uptake by host APCs).
  • an antigen e.g., toxin or pathogen
  • an "immune response” means (unless otherwise specified) an adaptive immune response to a specific antigen
  • an immune response involves the concerted action of lymphocytes, antigen presenting cells, phagocytic cells, and various soluble macromolecules in defending the body against infection or other exposure to non-self molecules.
  • the immune response can be detected and quantified (e.g., following immunization) by measuring cellular or humoral responses according to numerous assays known in the art (see, e.g., Coligan et al., 1991 (suppl. 1999), Current Protocols in Immunology, John Wiley & Sons (hereinafter, sometimes "Coligan”)).
  • T cell effector effects against cells expressing the antigen are detected using standard assays, e.g., target-cell killing, macrophage activation, B-cell activation or lymphokine production.
  • Humoral responses are measured by detecting the appearance of, or increase in titer of, antigen-specific antibodies using routine methods such as ELISA.
  • the progress of the antibody response can be determined by measuring class switching (i.e., the switch from an early IgM response to a later IgG response.
  • class switching i.e., the switch from an early IgM response to a later IgG response.
  • To enhance an immune response means (unless otherwise specified) to increase the vigor and/or magnitude and/or quality of the immune system being stimulated.
  • the early appearance of, or a high titer of, antigen-specific antibodies signifies (but does not limit the invention) a vigorous (enhanced) immune response.
  • a vigorous (enhanced) immune response Preferably, such magnitude is at least 2-fold, more preferably 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold and most preferably at least 10-fold.
  • An enhanced immune response also includes enhancing the immune response's quality, such as can be determine, for example that is meant to be non-limiting, higher affinity antibodies to the specific antigen, a greater presence of preferred IgGs, etc.
  • compositions According to the invention, a composition containing an APC chemotaxin is administered to induce or enhance an immune response in a subject.
  • the chemotaxin attracts dendritic cells, macrophages, or both. Chemotaxins that attract dendritic cells, particularly immature dendritic cells, are especially useful, hi a particularly useful embodiment, the chemotaxin has a high level of specificity for a particular cell type, developmental stage, or both.
  • the APC chemotaxin attracts immature dendritic cells, but does not attract one or more of the following other classes of cells: mature dendritic cells, neutrophils, monocytes, T cells, B cells, eosinophils, mast cells, red blood cells, and progenitor cells.
  • the APC chemotaxins of the invention maybe any of a large variety of compounds, both naturally occurring and synthetic, organic and inorganic, and including polymers (e.g., oligopeptides, polypeptides, oligonucleotides, and polynucleotides), small molecules, antibodies, sugars, fatty acids, nucleotides and nucleotide analogs, analogs of naturally occurring structures (e.g., peptide mimetics, nucleic acid analogs, and the like), and numerous other compounds.
  • the chemotactic compositions comprise polypeptides, such as naturally occurring chemokines, polypeptide variants, or mimetics of chemokines.
  • the composition contains at least one of the following: a chemokine polypeptide selected from hMCP2, hMCP3, hMIPl ⁇ , hMD?3 ⁇ , hMIP3 ⁇ , mMIG, mMIPl ⁇ , mMDC, vMIPl, mClO, a variant of an aforementioned chemokine, such as a recombinant polypeptide produced by in vitro mutation, in vitro recombination or shuffling of a polynucleotide encoding the chemokines, a polynucleotide encoding at least one of the aforementioned chemokines or variant molecules, or a synthetic (i.e., chemically synthesized) polypeptide variant (e.g., mimetic) of one or more of these chemokines.
  • a chemokine polypeptide selected from hMCP2, hMCP3, hMIPl ⁇ , hMD?3 ⁇ , hMIP
  • compositions of the invention Reagents and methods for, inter alia, identifying APC chemotaxins, and preparing and administering the compositions of the invention are described infra.
  • APC chemotaxins are identified using in vivo or in vitro assays.
  • the APC chemotaxins used in the methods of the invention have certain properties, which can be detected in in vitro chemotaxis assays.
  • In vitro chemotaxis assays are well known. Migration assays are often carried out by physically separating the cells from the chemoattractant using a porous membrane and allowing the cells to move directionally, up a diffusion gradient of the chemotaxin (see, e.g., Keller, 1972, Agents Actions 2:161-69; Gee A.P., 1984, Mol. Cell. Biochem. 62:5-11; Keller et al, 1974, Antibiot. Chemother. 19:112-25).
  • filter based assays include a classical or modified Boyden chamber and variants (see, e.g., Bozarth et al, 1997, Meth. Cell Science, 19:179-187; Frevert et al, 1998, J. Imm. Methods, 213:41-52; Penno et al, 1997, Meth. Cell Science, 19:189-195; O'Leary et al, 1997, Am. J. Resp. Cell and Mol. Bio., 16:267-274; Falk, et al, 1980, /. Imm.
  • Migration of cells at a level above background i.e., migration in the absence of the candidate chemotaxin, e.g., in the presence of only a carrier such as PBS or Chemotaxis buffer (infra) indicates that the candidate chemotaxin is indeed chemotactic for the target cell type. Conversely, when the number of migrating cells is at or below background, the candidate chemotaxin is considered, not chemotactic for the target cell type.
  • One suitable apparatus for carrying out in vitro chemotaxis assays is a 96-well ChemoTx® microplates (Neuroprobe h e. Gaithersburg MD).
  • the ChemoTx® instrument has a 96 well microplate of injection-molded from tissue-culture grade, transparent polystyrene.
  • the microplate provides bottom wells for chemoattractants and other reagents.
  • a framed filter is used that confines each cell-suspension sample to its site on top of the filter.
  • the 96 sites on the filter correspond to the 96 wells in the microplate and cell suspension pipetted directly onto the sites on the top side of the filter sit in hemispherical drops during incubation. After incubation the migrated cells on the filter and in the microplate are counted. See, U.S. Pat. No. 5,284,753.
  • candidate chemotaxins are added to lower wells (e.g., about 30 microliters) at one or more concentrations (e.g., about 1 nM, about 10 nM, about 100 nM, about 10 ng/ml, about 100 ng/ml and/or about 1 ⁇ g/ml), and cells are placed on porous polycarbonate filters positioned above the chemotaxin solution in each well.
  • the filters have a pore size of about 3 ⁇ m, or about 5 ⁇ m, so that only cells exposed to an agent chemotactic for the cell will migrate into and/or through the filter.
  • the microplate configuration about 20 microliters of cells (at about 1 x 10 6 to about 1 x 10 cells per ml, e.g., 5 x 10 cells per ml) are usually used.
  • the cells are incubated for a period of time (e.g., 0.5 to 6 hours, usually about 1.5 h, at from about 22°C to about 39°C, usually 37°C) and the cells are allowed to migrate into or through the filter.
  • the assay conditions are usually tailored to the cell type being studied. For example, cells that are relatively plastic are able to crawl through certain filters, where as others become “stuck” in the filter.
  • monocytes exposed to a monocyte chemotactic agent migrate through a 5 ⁇ m filter (into the lower chamber supernatant) which, in contrast, immature or mature dendritic cells exposed to a chemotactic agent migrate into a 3 ⁇ m or 5 ⁇ m filter, but are retained in the filter (i.e., the cells do not migrate through the filter).
  • the choice of migration assay format and the method of quantification can vary depending on the type of cells studied. For example, a 5 ⁇ m pore size is usually used for a monocyte migration assay; the assay is typically carried out for 90 minutes, and the migrating cells (if any) are detected in the well. For mature dendritic cells, a 3 ⁇ m pore size filter and 90 min incubation are used, and the cells are detected in the filter. These and other exemplary assay conditions are shown in Table 1. However, it will be appreciated that, as noted supra, a number of different assay formats and conditions can be used to determine that an agent does (or does not) have chemotactic activity (e.g., for a particular cell).
  • Table 1 also provides exemplary positive and negative controls for use in assays. Positive controls are agents that, when used at 100 nM concentration, have chemotactic activity. Negative controls are agents that, when used at 100 nM concentration, do not have chemotactic activity.
  • the number of cells that have migrated in the presence of the agent can be determined using a variety of methods.
  • To assay cells (e.g., dendritic cells) that are caught in a filter the filters are scraped to remove nonadherent cells (i.e., cells that have simply settled onto the top side of the filter) and the cells that have moved into the filter or adhered to its lower surface are quantitated.
  • nonadherent cells i.e., cells that have simply settled onto the top side of the filter
  • the cells that have moved into the filter or adhered to its lower surface are quantitated.
  • For cells that are able to migrate through the filter e.g., monocytes
  • the filter can be discarded and the number of cells that have migrated through the filter into the "lower" (chemotaxin-containing chamber) is determined.
  • Suitable cell quantitation methods include direct (microscopic) counting of migrated cells, histological, cytochemical, immunofluorescence (using antibodies to cell-specific or stage-specific markers), and in situ staining methods, use of radiolabled cells, and assays for RNA or DNA content (e.g., using reagents such CyQuant, Molecular Probes, Eugene OR, e.g., on a lysed cell extract), protein content (e.g., using stains such as Hema3), enzyme activity (e.g., ⁇ -glucuronidase), and the like. Often it is convenient to select stains that can be detected using densitometric or fluorescence plate readers.
  • concentrations of the candidate chemotaxin are used to detect an active concentration, e.g., at least two, typically at least three different concentrations, over a range of at least 10-fold, typically at least 100-fold, frequently at least 1, 000-fold, and often at least 10,000-fold differences.
  • the chemotaxis assays can be carried out using a heterogeneous mixture of cells (e.g., peripheral blood mononuclear cells (PBMCs)) or a purified subpopulation (e.g., immature DCs, mature DCs, neutrophils, monocytes and the like) or tissue culture cells derived from a certain cell type and with characteristics of those cells (e.g., THP1 (an acute monocytic leukemia cell line, CEM acute lyphoblastic leukemia, T lymphoblast cell line).
  • PBMCs peripheral blood mononuclear cells
  • a purified subpopulation e.g., immature DCs, mature DCs, neutrophils, monocytes and the like
  • tissue culture cells derived from a certain cell type and with characteristics of those cells
  • THP1 an acute monocytic leukemia cell line, CEM acute lyphoblastic leukemia, T lymphoblast cell line
  • the cell type or developmental stage of migrating cells is
  • the assay is carried out using a homogeneous preparation (e.g., substantially purified neutrophils), it is not necessary to determine the cell type of migrating cells because any cells that migrate to the chemotaxin can be presumed to be of that type.
  • a homogeneous preparation e.g., substantially purified neutrophils
  • a candidate chemotaxin is considered chemotactic for a particular cell type if the candidate chemotaxin, at a concentration about between about 1 pM and about 1 ⁇ m, e.g., between about 1 nM and 500 nM, e.g., 1 nM, about 10 nM, about 100 nM, or between about 1 pg/ml and about 10 ⁇ g/ml , e.g., between about 1 ng/ml and 1 ⁇ g/ml, e.g., about 10 ng/ml, about 100 ng/ml or about 1 ⁇ g/ml, attracts the cell at least 2-fold, preferably at least 4-fold, and often at least 8-fold more than "chemotaxis buffer" (a negative control) in an in vitro assay.
  • chemotaxis buffer a negative control
  • Chemotaxis buffer is 0.1% BSA (Sigma) in HBSS (Life Technologies), with 1.4 mM Ca 4"1" and 1 M Mg "1"” ".
  • HBSS is Hank's Balanced Salt Solution (CaCl 2 (O.Ug/l), KC1 (0.4g/l), KH 2 PO 4 (0.06g/l), MgCl 2 -6H 2 0 (OJg/l), MgSO 2 -7H 2 0 (OJg/1), NaCl (8g/l), NaHCO 3 (0.3g/l), Na 2 HPO 4 (0.048g/l), D-glucose (lg/1)).
  • An alternative negative control is PBS.
  • a candidate chemotaxin is considered not to be chemotactic for a cell type if the candidate chemotaxin, at a concentration 1 nM, 10 nM, 100 nM, or 10 ng/ml, 100 ng/ml or 1 ⁇ g/ml, does not attract more cells (e.g., at least as many, sometimes at least 1.5-fold as many) as the negative control in an in vitro assay.
  • a candidate chemotaxin is considered chemotactic for a particular cell type if the candidate chemotaxin, when injected at 2 ⁇ g, alternatively 10 ⁇ g, often 20 ⁇ g, attracts the cell at least 2-fold, preferably at least 5-fold, and often at least 10-fold more than PBS (a negative control) in an in vivo assay (e.g., intradermal injection into a mouse or monkey),
  • a candidate chemotaxin is considered not chemotactic for a cell type if the candidate chemotaxin, when injected at 2 ⁇ g, alternatively 10 ⁇ g, often 20 ⁇ g, does not attract more cells of the type (e.g., at least as many, sometimes at least 1.5 -fold as many) that the negative control in an in vivo assay.
  • PBS is phosphate buffered saline (KC1 (0.2g/l), KH 2 PO 4 (0.2g/l), NaCl (8.0g/l), Na 2 HPO4 (2J6g/l)).
  • an agent is determined to be a chemotactic agent because it has greater chemotactic activity than a known chemotaxin (e.g., known in the art or determined by the assays described herein).
  • Non-filter based chemotaxis assays may also be used, e.g., a cell migration assay can be carried out using a monolayer of cells grown on the filter as a barrier.
  • cellular motility may also be assessed by monitoring the movement of a single cell under a video microscope.
  • the chemoattractant is applied through capillary, and the physical distance of cell's lateral movement toward the source of the chemoattractant is recorded, (b) In vivo assays
  • the chemotactic properties of an agent can be determined in animals, e.g., mammals such as non-human primates and mice, as described in Examples 2-4, infra.
  • the candidate chemotactic agent e.g., 2-20 ⁇ g in PBS
  • the animal is euthanized, or a biopsy is taken.
  • the area around the injection site is excised and subjected to routine histology or immunohistology techniques to determine the presence or absence of cell infiltration and, if an infiltrate is present, to characterize and quantitate the infiltrating cells (see, e.g., mononuclear cells, neutrophils, dendritic cells, etc.).
  • cells are characterized by preparing frozen sections and staining with cell type specific antibodies, or cell type-specific combinations of antibodies, using well known methods (see, Harlow et al, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory).
  • enriched or substantially purified cell populations can be used in in vitro chemotaxis assays. These cell populations can be prepared by a variety of methods known in the art, depending on the specific cell-type desired. Typically, substantially purified cell populations are prepared by culture under specific conditions, by physical characteristics such as behavior in a density gradient, by sorting according to characteristic markers (e.g., by fluorescence activated cell sorting (FACS) using monoclonal antibodies to cell-surface proteins, immunoprecipitation), or other methods.
  • FACS fluorescence activated cell sorting
  • Cells e.g., in an enriched sample in vitro or in an infiltrate in vivo
  • can be identified histologically see, e.g., Luna, supra
  • immunological staining and similar methods (see, e.g., Harlow, supra; Coligan et al, supra).
  • Table 2 A and 2B list exemplary markers useful for characterizing or purifying (e.g., FACS sorting) certain immune system cells.
  • monocytes are isolated from PBMC by depletion of T cells using immobilized antibodies against a pan T cell surface marker CD2.
  • CD2 antibodies attached to magnetic beads Dynal
  • PBMC isolated from a buffy coat typically 35 mis containing 400 x 10 6 PMBC
  • MACS buffer made up of DPBS (HyClone) with 1% BSA (Sigma)
  • DPBS is Dulbecco's Phosphate Buffered Saline (CaCl 2 (O.lg/1), KC1 (0.2g/l), KH 2 PO (0.2g/l), MgCl 2 -6H 2 0 (O.lg/1), NaCl (8.0g/l), Na 2 HPO4 (2.16g/l)).
  • An appropriate amount of immobilized CD2 + magnetic beads (typically 10 ⁇ l per 10 6 cells) are added to the cells. The mixture is incubated for 15 minutes at 4°C with gentle rotation. The magnetically tagged T cells are removed from the unlabeled cells on a magnetic cell sorter (Dynal) according to the manufacturer's protocols.
  • the unlabeled cells contain primarily monocytes and B cells.
  • B cells in the above preparation are removed by the conventional plastic adherence method. Briefly, PBMC depleted of T cells are allowed to adhere to the plastic of a T-175 tissue culture flask (100 x 10 6 cells/ flask) (Costar) for 3 hours at 37°C. Non-adherent cells (comprising largely B cells) are aspirated. The flasks are rinsed 3 more times with DPBS to completely remove non-adherent cells. The resulting cells are largely enriched (i.e., > 90%) for monocytes.
  • Monocytes can also be isolated by positive selection of CD 14 antigen. Briefly, PBMC isolated from peripheral blood, such as a buffy coat, by the standard Ficoll gradient centrifugation method are resuspended in MACS buffer at 1 x 10 6 cells/ml. Immobilized antibodies against the CD 14 surface antigen, such as CD 14+ magnetic microbeads (Milteyni) are added (1 ⁇ l of beads per lxlO 6 cells) and the mixture is incubated at 4°C for 15 minutes. Monocytes are separated from the other cell populations by passing the mixture through a positive selection column on a magnetic cell sorter (Miltenyi) according to manufacturers protocol.
  • CD 14+ magnetic microbeads such as CD 14+ magnetic microbeads (Milteyni)
  • Monocytes that are retained on the column are eluted with MACS buffer after the column is removed from the MACS apparatus. Cells are then pelleted by centrifugation and resuspended in RMPI plus 10% FCS media at 10 6 cells per ml. Monocytes isolated by this method are cultured essentially the same way as those isolated by the CD2+ depletion method.
  • Suitable methods for purification of dendritic cells including separate mature and immature populations, are known in the art.
  • Substantially purified dendritic cells can be prepared by selective in vitro culture conditions.
  • Dendritic cells are widely distributed in all tissues that have contact with potential pathogens (e.g., skin, gastrointestinal and respiratory tracts, and T cell-rich areas of the secondary lymphoid tissues). In the skin and upper respiratory tract they form a lattice of highly arborised cells (called Langerhans cells in the skin). After capturing antigen, dendritic cells in the peripheral tissues such as the skin and gut, traffic via the draining lymphatics to the T cell areas of lymph nodes where they present the antigen that was internalized at the point of pathogen contact. Immature dendritic cells function to take up and process antigens. During subsequent migration to the draining lymph node, the DC matures. The mature dendritic cells functions as the key APC to initiate immune responses by inducing the proliferation of pathogen specific cytotoxic and helper T cells.
  • pathogens e.g., skin, gastrointestinal and respiratory tracts, and T cell-rich areas of the secondary lymphoid tissues.
  • pathogens e.g.
  • Substantially pure populations of dendritic cells can be produced by in vitro culture see, infra).
  • chemokine receptors during dendritic cell maturation which can be used to identify cell stage
  • dendritic cells In culture, immature forms of dendritic cells undergo maturation thought to be analogous to what occurs during the migration of dendritic cells from the point of antigen contact until their residence in the secondary lymphoid tissues.
  • Human or macaque dendritic cells of various developmental stages can be generated in culture, from CD14 + blood progenitors using specific cytokines.
  • a separate lineage of dendritic cells can be differentiated from CD34+ precursor cells from cord blood or bone marrow.
  • subpopulations of dendritic cells are generated for in vitro assays for identification of chemotactic compositions (i.e. to assess chemotaxin potency and selectivity against defined DC sub-types).
  • Exemplary subpopulations of dendritic cells are: (1) immature peripheral blood monocyte derived cells; (2) mature peripheral blood monocyte derived cells, and (3) cells derived from CD34+ precursors. Subpopulations are isolated or produced by a variety of methods known in the art.
  • PBMCs are depleted of T cells using immobilized antibodies against the cell surface marker CD2 (present on all T cells).
  • CD2+ dynabeads can be used according to manufacturer's protocol.
  • the T-cell depleted mixture is separated into adherent versus non-adherent fractions by incubation of the cells on tissue culture grade plastic for 3 hours at 37°C. Adherent cells attach to the surface within the 3 hours while the non-adherent cells remain in suspension.
  • Non-adherent cells are gently removed and adherent cells (generally CD14 + monocytes) are placed in culture media (e.g., RMPI + 10% FCS) supplemented with 1000 U/mL each of GM-CSF and IL-4 (R&D Systems, Minneapolis, MN) ("Day 1"). Between days 3-7 the cells begin to display a veiled morphology, and cytokines are replenished on days 2, 4, and 6, at which time the cells can be harvested as immature dendritic cells. In one embodiment, cells of this stage in vitro are isolated and used in the assay. Approximately 10 x 10 6 dendritic cells are typically obtained from 400 x 10 6 PBMCs.
  • Immature dendritic cells (generated from peripheral blood monocytes or from bone marrow derived CD34+ precursors), can be further activated and differentiated to become mature dendritic cells. Two methods are primarily used: MCM
  • RNA-ploy stimulation (macrophage conditioned medium) and double-stranded RNA-ploy (I:C) stimulation (Cella et al, 1999, JExp Med. 189:821-9; Verdijk et al, 1999, J Immunol. 1999 1:57- 61).
  • day 6 immature dendritic cells are harvested by centrifugation and resuspended in at 10 6 cells/ml in maturation medium (e.g. , MCM diluted (up to 1 :1 with RPMI containing 10% FCS).
  • maturation medium e.g. , MCM diluted (up to 1 :1 with RPMI containing 10% FCS).
  • GM-CSF 1000 U/ml
  • JL-4 1000 U/ml
  • Cells are cultured for three more days, without further addition of GM-CSF (1000 U/ml) and JX-4. Day 9 cells are used as mature dendritic cells.
  • day 6 immature dendritic cells are harvested and resuspended in the standard culture medium (RPMI plus 10% FCS) supplemented with 20 ⁇ g/ml of poly (I:C) (Sigma), 1000 U/ml of GM-CSF and IL-4. Cells are cultured for another three days without additional cytokines. Day 9 cells are mature dendritic cells. Mature dendritic cells generated by these two different methods exhibit phenotypic and functional properties distinct from those of immature dendritic cells or the precursor monocytes (See Table 2A). Mature dendritic cells from each preparation are thoroughly characterized by FACS to ensure that the desirable cell types are obtained. Notably, mature dendritic cells generated express significantly higher level of
  • Expression of CD 80, CD83 and CD86 are also up-regulated.
  • Chemokine receptor expression also changes dramatically during the maturation process. For instance, CCR1, CCR5 are down- regulated sharply in mature cells, while CCR7 is up-regulated and appears on the cell surface within a few hours after addition of MCM.
  • mature dendritic cells are no longer capable of taking up antigen efficiently, but gain the ability to stimulate the proliferation of na ⁇ ve T cells and B cells.
  • Mature dendritic cells also changes their migratory behaviors; they no longer respond to ligands of CCR1, CCR2, CCR5 such as MlP-l ⁇ , RANTES and MIP-IB. Instead, they respond to CCR7 ligands SLC and ELC.
  • MCMMedia MCM is prepared by as described by Romani et al, 1996, J. Immunol.
  • the TNF-a concentration in the MCM is determined by the standard ELISA method (e.g., using a TNF-a ELISA kit (R&D Systems, Minneapolis, MN)).
  • the final TNF-a level in MCM is adjusted to 50 U/ml by mixing an appropriate amount of MCM with RPMI with 10% fetal calf serum.
  • Suitable methods for purification of neutrophils are known in the art.
  • whole fresh blood (WB) is diluted 1 : 1 with 3% dextran in a 50 ml centrifuge tube, and allowed to sediment for 30 - 45 in at room temperature.
  • 25 ml of WB plus 25 ml dextran results in approximately 35 ml of supernatant after 30 min sedimentation.
  • the supernatant is layered over 12-15 ml Ficoll and centrifuged at 400 x g for 30-40 min at 18-20°C.
  • the plasma/platelet layer containing mononuclear cells and Ficoll-Paque are removed by aspiration.
  • Neutrophils are found in the white layer above the erythrocyte (RBC) layer.
  • RBC erythrocyte
  • the neutrophil and erythrocyte layers are mixed.
  • RBCs are removed by hypotonic lysis in the following manner: 12.5 ml of cold 0.2% NaCl is added to the neutrophils/RBC pellet while vortexing. 12.5 ml of cold 1.6% NaCl is Immediately added while still vortexing. The cells are centrifuged at 60- 100 x g for 10 m and recovered. If necessary the lysis step is repeated.) The resulting neutrophils are >95% pure (with the eosinophis as the primary remaining cells).
  • Suitable methods for purification of macrophages are known in the art. One suitable method is described in Paluka et al, 1998, "Dendritic cells as the terminal stage of monocyte differentiation,” JImm. 9:4587-95.
  • T lymphocytes are routinely prepared by removal of monocytes from the PBMC prepared by the standard Ficoll gradient centrifugation method (Coligan, supra).
  • the non-adherent cells are cultured in RPMI + 10% FCS in the presence of a combination of PHA (5 ⁇ g/ml) and human recombinant E -2 (20 ng/ml) for two weeks, and the cells are harvested for assay.
  • Suitable methods for purification of B cells are known in the art. Highly purified B cell populations are isolated by negative selection with sequential depletion of monocytes/natural killer cells and T cells (as described in Current Protocols in Immunology). Depletion of monocytes and NK cells are carried out by using L- leucine methyl ester (L-LME). Briefly, PBMC isolated from peripheral blood (e.g, from a buffy coat) by the standard Ficol gradient method are resuspended at 3xl0 6 cells/ml in PBS. Freshly prepared L-LME (0.05 M solution in RPMI, no serum) is added to cells at 1:10 dilution (5 mM final).
  • L-LME L- leucine methyl ester
  • the mixture is incubated for 35 minutes at room temperature, the cells are pelleted by centrifugation, followed by washing 3x with PBS. T cells are further depleted by rosetting with neurominidase-treated sheep red blood cells (NSRBC) in the following manner: Cells are adjusted to 10 7 cells/ml in RPMI/10% FCS. 5 ml of cells are transferred into a 50 ml centrifuge tube. 2.5 ml of fetal calf serum and 2.5 ml of NSRBC are added to the tube. The mixture is incubated for 10 minutes at 37°C. The cells are then centrifuged at 150xg at room temperature for 10 minutes to pellet cells and promote rosette formation. The mixture is incubated at 4°C for 2 hours.
  • NSRBC neurominidase-treated sheep red blood cells
  • the pellet is gently resuspended, and the cell suspension is underlaid with Ficol (10ml).
  • the tube is centrifuged at 400xg for 25 minutes. B cells in the interface are removed, pelletted and washed three times with HBSS. After repeating the rosetting step, B cells are resuspended in RPMI/10% FCS for migration assays.
  • Suitable methods for purification of eosinophils are known in the art.
  • One method for preparation of substantially purified eosinophils is by further isolation from the preparation described in the neutrophil isolation protocol, supra. Separation of eosinophils form neutrophils is achieved by a negative selection method, where immobilized antibodies against the CD 16 surface antigen are used to deplete the CD 16 positive neutrophils. Briefly, the neutrophil preparation is resuspended in MACS buffer (1% BSA in DPBS) at a density of 10 6 cells/ul. An equal volume of CD 16+ microbeads (CD 16 immobilized on magnetic spheres; Miltenyi Biotech; Auburn, CA) is mixed with the cells.
  • the mixture is incubated at 4°C with gentle shaking for 30 minutes.
  • Cells are then passed through a negative selection column that removes the magnetically labeled neutrophils (CS column, Miltenyi Biotech; Auburn, CA) LC, Miltenyi) and the column is washed with one column volume of MACs buffer.
  • the flow-through and wash fractions contain eosinophils and are combined. Eosinophils isolated by this method are more than 95% pure (as determined by FACS, e.g., for the presence of the CD16+ cells).
  • the APC chemotaxins of the invention maybe any of a number of types of compounds.
  • the chemotaxin is a protein, such as a chemokine, or a protein mimetic.
  • the chemotactic composition comprises one or more chemokines, chemokine analogues, or chemokine-encoding polynucleotides.
  • Chemokines are protein hormones that, among other activities, direct trafficking of white blood cells populations, e.g., in the primary lymphoid organs, blood, tissues, secondary lymphoid organs, lymph, and (in some instances), back into circulation. Over 50 distinct chemokines have been identified to date in humans, and numerous chemokines from other mammals and chemokines encoded by mammalian viruses are known.
  • chemokines are divided into four classes: CC, CXC, C, and CX3C, based on the number and spacing of the amino-terminal cysteine residues in a conserved structural motif. Chemokines exert promigratory effects by binding to an array of cell surface receptors on the surface of target leukocytes. Known receptors are of the seven transmembrane spanning, G protein coupled receptor (7TM GPCR) class.
  • CCR CC chemokine receptors
  • CXCR CXC chemokine receptors
  • CX3CR CX3C chemokine receptor
  • C chemokine receptor provisionally 'XCR'
  • one promiscuous chemokine receptor of broad binding specificity originally known as the Duffy blood group antigen (Duffy Ag, sometimes denoted 'DARC') is known.
  • Chemokine proteins can be obtained from suppliers, e.g., R&D Systems
  • chemokines used in, or to prepare, the compositions of the present invention may be natural (i.e., have the sequence of a naturally occurring chemokine), maybe the product of in vitro recombination of polynucleotides encoding naturally occurring chemokines, or may be synthetic (i.e., chemically synthesized) or recombinant variants of naturally occurring chemokine sequences.
  • Chemokines comprise sequences from human, primate, rodent, viral, and other species.
  • xenogeneic sequences are used in the vaccination methods of the invention (e.g., if the most potent chemokine is from a species other than the species of the subject being immunized) because any immunogenic effects will likely enhance the adjuvant activity.
  • the compositions contain at least one chemokine polypeptide that is an APC chemotaxin.
  • the chemokine is chemotactic for human immature (antigen uptake competent) monocyte derived dendritic cells.
  • chemokines are chemotactic for immature but not mature dendritic cells, including: hMIPl ⁇ , hMIPl ⁇ (70aa), mMJP-l ⁇ , hRANTES, hMET-RANTES, mRANTES, hHCC-1, hMPIF-1, hMPIF-1 (22-137), hMPTF-1 (46-137), hMIP-l ⁇ , hMCP-4, mMCP-5, mMARC, mEotaxin, mMCP-l(JE), mTECK, mMJP-2, mBLC, hLeukotactin, mMIG, and mMIP-1 ⁇ .
  • chemokines of the invention include hMCP-2, hMCP-3, vMIP-1, hMJP-3 ⁇ , hMIP-3 ⁇ , and vMCK-2 (see Examples, infra).
  • chemokines were chemotactic for immature dendritic cells but were not chemotactic for neutrophils and other cell types tested in in vitro assays (mClO, mMDC, hMIP-l ⁇ , mMIP-l ⁇ ; see Table 3).
  • chemokines and their variants and derivatives are especially useful in the compositions and vaccination methods of the invention.
  • an APC chemotaxin molecule has the sequence of a naturally occurring chemotaxin molecule or has an amino acid sequence with substantial amino acid sequence identity to the sequence of a naturally occurring chemotaxin molecule.
  • chemokine polypeptides such as the chemokines listed in supra, can be modified in ways that do not change the chemotactic properties of the naturally occurring polypeptide, for example, by conservative amino acid substitutions, truncations (especially at the termini), small internal deletions, insertions, and the like. Such modifications can be made using routine genetic engineering techniques, e.g., using site-directed mutagenesis, and the resulting mutants assessed for chemotactic properties (e.g., using the assays disclosed herein).
  • recombinant and synthetic techniques can be used to modify naturally occurring chemokine molecules or sequences (including, but not limited to those listed supra and in Table 3) to modify the chemotactic properties of the polypeptide compared to the parent polypeptide(s).
  • Engineered chemokines are prepared and assessed for the ability to mobilize APCs (e.g., dendritic cells), h one embodiment, APC chemotaxins are generated from a combination of natural chemokines using synthetic or recombinant DNA technology.
  • APC chemotaxins are generated from a combination of natural chemokines using synthetic or recombinant DNA technology.
  • different chemokines e.g., human, viral, murine, and the like
  • can be recombined e.g., genetically to form chimeras or "hybrikines" that are tested for the desired activity (e.g., the ability attract immature dendritic cells but not neutrophils, enhanced chemoattractant activity at lower concentrations).
  • the chimeras are chemically synthesized based on the sequence of parent (e.g., naturally occurring) chemokines.
  • the sequences of chemokine polypeptides of interest are divided into four 'domains' as dictated by the spacing of the cysteine residues (see Fig. 2 and Example 5).
  • the sequences are divided into multiple "domains" (e.g., 2, 3, 4, or more) of any length (but typically at least 5, more often at least 10 residues), for the purpose of constructing hybrids.
  • sequences are conceptually recombined to form chimeric sequences, in which one region has a sequence of a first chemokine polypeptide and a second region has the sequence of a second chemokine polypeptide, as illustrated in Fig. 2.
  • Chimeric polypeptides (hybrikines) having the chimeric sequence are then produced by routine synthetic means (or, alternatively, by using recombinant DNA techniques, as described infra), Polypeptide synthetic methods are well known in the art and are described in, e.g., U. S. Pat. No. 4,108,846; see also, Caruthers et al, 1980, Nucleic Acids Res. Symp.
  • short polypeptides may be fused by condensation of the amino terminus of one molecule with the carboxyl terminus of the other molecule to form a peptide bond to produce a longer polypeptide.
  • the newly synthesized peptide can be substantially purified, for example, by preparative high performance liquid chromatography (e.g., Creighton, 1983, Proteins, Structures, and Molecular Principles, W.H. Freeman and Co, New York NY).
  • the polynucleotides encoding parent chemokines of interest are manipulated to produce variant or chimeric chemokines such as those described supra (e.g., the polynucleotide is divided into multiple 'domains' as dictated by the spacing of the cysteine residues of the encoded polypeptide and hybrid gene constructs) or chemically synthesized polynucleotides are prepared.
  • the hybrid genes are subcloned into appropriate expression vectors and introduced (e.g., transfected) into host cells (e.g., bacterial or eukaryotic cells) and the cells are cultured under conditions in which the recombinant protein is expressed.
  • chimeric molecule comprises at least 10 contiguous residues from each of at least two different naturally occurring chemokines.
  • at least one of the naturally occurring chemokines are selected from: hMIPl ⁇ , hMTPl ⁇ (70aa), mMIP-1 ⁇ , hRANTES, hMET-RANTES, mRANTES, hHCC-1, hMPIF-1, hMPIF-1 (22-137), hMPIF-1 (46-137), hMIP-l ⁇ , hMCP-4, mMCP-5, mMARC, mEotaxin, mMCP-l(JE), mTECK, mMIP-2, mBLC, hLeukotactin, mMIG, and mMIP-l ⁇ , hMCP-2, hMCP-3, vMIP-1, hMIP-3 ⁇ , hMIP-3 ⁇ , vMIP-1, hMIP-3 ⁇ , hMIP-3 ⁇ , vMIP
  • chemokines with enhanced dendritic cell attractant properties and decreased recruitment of non-dendritic immune cells, are constructed using different hybrids of human and viral chemokines.
  • an APC chemotaxin e.g. a chemokine
  • an APC chemotaxin with potent dendritic cell chemotactic activity but undesired neutrophil chemotactic activity can be recombined with a polypeptide with weaker dendritic cell activity and no neutrophil chemotactic activity to produce a polypeptide with strong dendritic cell activity and no neutrophil chemotactic activity.
  • derivatives of chemokines with enhanced properties are constructed using forced in vitro genetic evolution using any of several routine techniques, including error-prone PCR or recombination/gene shuffling approaches.
  • Methods for generating new polypeptides with desired activities by gene "shuffling" are known in the art.
  • shuffling methods are described in Patten et al, 1997, Curr. Opin. Biotech. 8:724-733; Stemmer, 1994, Nature 370:389-391; Stemmer et al, 1994, Proc. Natl. Acad. Sci.
  • One method of gene shuffling conducting a polynucleotide amplification process on overlapping segments of a population of variants of a polynucleotide under conditions whereby one segment serves as a template for extension of another segment, to generate a population of recombinant polynucleotides, and screening or selecting a recombinant polynucleotide or an expression product thereof for a desired property.
  • Some methods of shuffling use random point mutations (typically introduced in a PCR amplification step) as a source of diversity. The resulting polypeptides are tested for chemotactic activity as described above.
  • the gene shuffling is carried out beginning with a polynucleotide encoding a particular chemokine (e.g., l ⁇ MCP2, hMCP3, hMTPl ⁇ , hMIP3 ⁇ , hMIP3 ⁇ , mMIG, mMIPl ⁇ , mMDC, vMIPl, mClO).
  • a particular chemokine e.g., l ⁇ MCP2, hMCP3, hMTPl ⁇ , hMIP3 ⁇ , hMIP3 ⁇ , mMIG, mMIPl ⁇ , mMDC, vMIPl, mClO.
  • family shuffling is used (see, e.g., Cramer et al, 1998, Nature 152:88- 91; Chang et al, 1999, Nat Biotechnol 17:793-7) and at least two "parental" chemokine-encoding polynucleotides are used in the family shuffling reaction.
  • At least one of the parental chemokine-encoding polynucleotides encodes hMIPl ⁇ , hM l ⁇ (70aa), mMJP-l ⁇ , hRANTES, hMET-RANTES, mRANTES, hHCC-1, hMPIF-1, hMPIF-1 (22-137), hMPIF-1 (46-137), hMIP-l ⁇ , hMCP-4, mMCP-5, mMARC, mEotaxin, mMCP-l(JE), mTECK, mMIP-2, mBLC, mMIP-l ⁇ , mMIG, and mMIP-l ⁇ , hMCP-2, hMCP-3, vMIP-1, hMIP-3 ⁇ , hMJP-3 ⁇ , mClO, mMDC, hMIP-l ⁇ , vMCK-2, and hLeukotactin or a species homo log thereof.
  • At least two of the parental chemokine-encoding polynucleotides encode a chemokine from the group hMIPla, hMIPl ⁇ (70aa), rnMIP- l ⁇ , hRANTES, hMET-RANTES, mRANTES, hHCC-1, hMPIF-1, hMPIF-1 (22- 137), hMPIF-1 (46-137), hMIP-l ⁇ , hMCP-4, mMCP-5, mMARC, mEotaxin, rriMCP- 1(JE), mTECK, mMIP-2, mBLC, mMff-l ⁇ , mMIG, and mMIP-l ⁇ , hMCP-2, hMCP- 3, vMIP-1, hMIP-3 ⁇ , hMIP-3 ⁇ , mClO, mMDC, hMIP-l ⁇ , vMCK-2, and
  • a parental APC chemotaxin e.g. , chemokine
  • in vitro mutagenesis methods e.g., site directed mutagenesis (Ausubel, supra) or in vitro genetic manipulation of chemokine- encoding polynucleotides.
  • the activity of the resulting variant can be determined using the in vitro and in vivo assays described herein.
  • chemokine e.g., a chemokine
  • chemokine-encoding polynucleotide e.g., a chemokine
  • these truncated version of the APC chemotaxin can be chemically synthesized, or produced by enzymatic processing of a naturally occurring chemokine.
  • variants with conservative substitutions that retain the desired properties may be used in the methods and compositions of the invention.
  • Conservative substitution tables providing functionally similar amino acids are well known in the art.
  • one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution): ala/gly or ser; arg/ lys; asn/ gin or his; asp/glu; cys/ser; gln/asn; gly/asp; gly/ala or pro; his/asn or gin; ile/leu or val; leu/ile or val; lys/arg or gin or glu; met/leu or tyr or ile; phe/met or leu or tyr; ser/thr; thr/ser; trp/tyr; tyr/trp or phe; val/ile or leu.
  • An alternative exemplary guideline uses the following six groups, each containing amino acids that are conservative substitutions for one another:
  • Polypeptide mimetics are also suitable for use in the methods of the invention.
  • the terms "mimetic” and “peptidomimetic” refer to a synthetic chemical compound which has substantially the same structural and/or functional characteristics as an APC chemotaxin polypeptide of the invention (e.g., a specific chemokine).
  • the mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non- natural analogs of amino acids.
  • the mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or activity.
  • Polypeptide mimetic compositions can contain any combination of nonnatural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.
  • a secondary structural mimicry i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.
  • a polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds.
  • Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, ⁇ -hydroxysuccinimide esters, bifunctional maleimides, ⁇ , ⁇ '-dicyclohexylcarbodiimide (DCC) or N,N'- diisopropylcarbodiimide (DIG).
  • a polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues.
  • Nonnatural residues are well described in the scientific and patent literature; a few exemplary nonnatural compositions useful as mimetics of natural amino acid residues and guidelines are described below.
  • Mimetics of aromatic amino acids can be generated by replacing by, e.g., D- or L- naphylalanine; D- or L- phenylglycine; D- or L-2 thieneylalanine; D- or L-l, -2, 3-, or 4- pyreneylalanine; D- or L-3 thieneylalanine; D- or L-(2-pyridinyl)-alanine; D- or L-(3-pyridinyl)-alanine; D- or L-(2-pyrazinyl)-alanine; D- or L-(4-isopropyl)- phenylglycine; D-(trifluoromethyl)-phenylglycine; D-(trifluoromethyl)- phenylalanine; D-p-fluorophenylalanine; D- or L-p-biphenylphenylalanine; K- or L-p- methoxybiphenylpheny
  • Aromatic rings of a nonnatural amino acid include, e.g., thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl, naphthyl, furanyl, pyrrolyl, and pyridyl aromatic rings.
  • Mimetics of acidic amino acids can be generated by substitution by, e.g., non- carboxylate amino acids while maintaining a negative charge; (phosphono)alanine; sulfated threonine.
  • Carboxyl side groups e.g., aspartyl or glutamyl
  • Carboxyl side groups can also be selectively modified by reaction with carbodiimides (R' -N-C-N-R') such as, e.g. , 1 - cyclohexyl-3(2-morpholinyl-(4-ethyl) carbodiimide or l-ethyl-3(4-azonia- 4,4- dimetholpentyl) carbodiimide.
  • Aspartyl or glutamyl can also be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
  • Mimetics of basic amino acids can be generated by substitution with, e.g., (in addition to lysine and arginine) the amino acids omithine, citrulline, or (guanidino)- acetic acid, or (guanidino)alkyl-acetic acid, where alkyl is defined above.
  • Nitrile derivative e.g., containing the CN-moiety in place of COOH
  • Asparaginyl and glutaminyl residues can be deaminated to the corresponding aspartyl or glutamyl residues.
  • Arginine residue mimetics can be generated by reacting arginyl with, e.g., one or more conventional reagents, including, e.g., phenylglyoxal, 2,3-butanedione, 1,2- cyclohexanedione, or ninhydrin, preferably under alkaline conditions.
  • one or more conventional reagents including, e.g., phenylglyoxal, 2,3-butanedione, 1,2- cyclohexanedione, or ninhydrin, preferably under alkaline conditions.
  • Tyrosine residue mimetics can be generated by reacting tyrosyl with, e.g., aromatic diazonium compounds or tetranitromethane. N-acetylimidizol and tetranitromethane can be used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Cysteine residue mimetics can be generated by reacting cysteinyl residues with, e.g., alpha-haloacetates such as 2-chloroacetic acid or chloroacetamide and corresponding amines; to give carboxymethyl or carboxyamidomethyl derivatives.
  • cysteinyl residues e.g., alpha-haloacetates such as 2-chloroacetic acid or chloroacetamide and corresponding amines
  • Cysteine residue mimetics can also be generated by reacting cysteinyl residues with, e.g., bromo-trifluoroacetone, alpha-bromo-beta-(5-imidozoyl) propionic acid; chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide; methyl 2- pyridyl disulfide; p-chloromercuribenzoate; 2-chloromercuri-4 nitrophenol; or, chloro-7-nitrobenzo-oxa-l,3-diazole.
  • cysteinyl residues e.g., bromo-trifluoroacetone, alpha-bromo-beta-(5-imidozoyl) propionic acid
  • chloroacetyl phosphate N-alkylmaleimides
  • 3-nitro-2-pyridyl disulfide methyl 2- pyridyl disulfide
  • Lysine mimetics can be generated (and amino terminal residues can be altered) by reacting lysinyl with, e.g., succinic or other carboxylic acid anhydrides. Lysine and other alpha-amino-containing residue mimetics can also be generated by reaction with imidoesters, such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4, pentanedione, and transamidase-catalyzed reactions with glyoxylate.
  • imidoesters such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4, pentanedione, and transamidase-catalyzed reactions with glyoxylate.
  • Mimetics of methionine can be generated by reaction with, e.g., methionine sulfoxide.
  • Mimetics of proline include, e.g., pipecolic acid, thiazolidine carboxylic acid, 3- or 4- hydroxy proline, dehydroproline, 3- or 4-methylproline, or 3,3,- dimethylproline.
  • Histidine residue mimetics can be generated by reacting histidyl with, e.g., diethylprocarbonate or para-bromophenacyl bromide.
  • mimetics include, e.g., those generated by hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of seryl or threonyl residues; methylation of the alpha-amino groups of lysine, arginine and histidine; acetylation of the N-terminal amine; methylation of main chain amide residues or substitution with N-methyl amino acids; or amidation of C-terminal carboxyl groups.
  • a component of a natural polypeptide can also be replaced by an amino acid (or peptidomimetic residue) of the opposite chirality.
  • any amino acid naturally occurring in the L- configuration (which can also be referred to as the R or S, depending upon the structure of the chemical entity) can be replaced with the amino acid of the same chemical structural type or a peptidomimetic, but of the opposite chirality, generally referred to as the D- amino acid, but which can additionally be referred to as the R- or S- form.
  • the mimetics of the invention can also include compositions that contain a structural mimetic residue, particularly a residue that induces or mimics secondary structures, such as a beta turn, beta sheet, alpha helix structures, gamma turns, and the like.
  • a structural mimetic residue particularly a residue that induces or mimics secondary structures, such as a beta turn, beta sheet, alpha helix structures, gamma turns, and the like.
  • substitution of natural amino acid residues with D-amino acids; N- alpha-methyl amino acids; C-alpha-methyl amino acids; or dehydroamino acids within a peptide can induce or stabilize beta turns, gamma turns, beta sheets or alpha helix conformations.
  • Beta rum mimetic structures have been described, e.g. , by Nagai (1985) Tet. Lett. 26:647-650; Feigl (1986) J. Amer. Chem. Soc.
  • Beta sheet mimetic structures have been described, e.g., by Smith (1992) J. Amer. Chem. Soc. 114:10672-10674.
  • a type VI beta turn induced by a cis amide surrogate, 1 ,5-disubstituted tetrazol is described by Beusen (1995) Biopolymers 36:181 -200.
  • mimetics which can be incorporated into the polypeptide of the invention include those described by, e.g, Zhang (1998) Biochemistry 37:12465-12476, who constructed functionally active (R and S)-gamma-lactam confoimational mimetics using a 3-(R or S)-amino- 2-oxo-l- pyrrolidine-acetamido moiety in place of the Pro-Gly of the tridecapeptide Saccharomyces cerevisiae alpha-factor mating pheromone. Brady (1998) J. Med. Chem. 41:401-406, used a resin-based route for the synthesis of thrombin inhibitor mimetic with a range of lipophilic carboxylic amides.
  • Small Chemokine Mimetics hi an embodiment, small molecule chemokine mimetics are used to mobilize
  • small molecule mimetics are identified using high throughput screening technologies for small molecule compounds that bind chemokine receptors (CRs) and transduce signal (e.g., calcium ion mobilization or other chemokine receptor-mediated responses).
  • CRs chemokine receptors
  • transduce signal e.g., calcium ion mobilization or other chemokine receptor-mediated responses.
  • small molecules can be screened initially for the ability to agonize chemokine receptors that are expressed on immature dendritic cells and/or are not expressed on other cells (see, e.g., Table 2B).
  • the agonizing activity can be detected in a variety of ways, such as detecting Ca2+ mobilization responses on transfectant cells expressing cloned chemokine receptors known to be present on APCs.
  • chemotactic properties of the molecules are then determined using the assays described supra, and those with desired specificity (e.g., chemotactic for immature but not mature dendritic cells) are used in the methods of the present invention.
  • the chemotactic compositions of the invention contain one or more APC chemotaxins (or chemotaxin-encoding polynucleotides).
  • the composition contains an APC chemotaxin that is an isolated or recombinant polynucleotide or polypeptide.
  • the APC chemotaxin(s) is/are the predominant species (i.e., greater than about 50%, more often greater than about 80% by weight of the total of the members of the class of molecule in the composition) of its class (e.g., polypeptide, polynucleotide, lipid, carbohydrate) in the composition.
  • the APC chemotaxin(s) is “biologically pure.”
  • the words “isolated,” “pure” “substantially purified” or “biologically pure” refer to material which is substantially or essentially free from components which normally accompany it as found in its native state.
  • the chemotactic compositions of the invention contains APC chemotaxins free of materials normally associated with their in situ environment (if naturally occurring).
  • the isolated, chemotaxins of the invention are at least about 80% pure, usually at least about 90%, and preferably at least about 95%.
  • Protein purity or homogeneity may be determined by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualization upon staining. For certain purposes high resolution will be needed and HPLC or a similar means for purification utilized.
  • the compositions may additionally contain an excipient or carrier, such as described infra.
  • the composition includes one or more antigens (i.e. , the antigen to which it is desired to induce or enhance an immune response), as is discussed in greater detail infra.
  • the compositions may contain a conventional adjuvant. Conventional adjuvants typically convert soluble protein antigens into particulate material and often include bacteria or bacterial products.
  • Exemplary conventional adjuvants include Freund's incomplete adjuvant, Freund's complete adjuvant, Merck Adjuvant 65, AS-2, alum, aluminum phosphate, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol.
  • Other useful adjuvants include, but not limited to, bacterial capsular polysaccharides, dextran, LL-12, GM-CSF, CD40 ligand, IFN-gamma, IL-1, IL-2, IL-3, IL-4, IL-10, IL-13, IL-18, or any cytokine.
  • the invention provides a method of formulating a composition capable of inducing an immune response (that is, the composition possesses the characteristic of being able to elicit an immune response if administered) to an specified antigen in a subject by identifying a polypeptide having the activity of an antigen-presenting cell chemotaxin (APC chemotaxin) as described herein, and combining the polypeptide with the antigen, hi an embodiment, a pharmaceutically acceptable excipient is also included.
  • APC chemotaxin antigen-presenting cell chemotaxin
  • the present invention provides a method of eliciting or enhancing an immune response to an antigen, e.g., a predetermined or specified antigen.
  • An antigen is a molecule that reacts with an antibody.
  • the antigen is an immunogen.
  • the antigen is linked to a protein carrier.
  • an APC chemotaxin and an antigen are physically linked (e.g., made as a fusion protein, stably cross-linked using chemical cross-linkers, or linked via complexes such as biotin and streptavidin).
  • an antigen is a peptide, a polypeptide, chemical compound, microbial pathogen, bacteria (e.g., live, attenuated, or inactivated), a virus (including inactivated virus particles, modified live viral particles, and recombinant virus particles), a recombinant cell, glycoproteins, lipoproteins, glycopeptides, lipopeptides, toxoids, carbohydrates, tumor-specific antigens, and other immunogenic components of pathogens, hi one embodiment, mixtures of two or more antigens are employed.
  • the antigen is biologically pure.
  • the methods and reagents of the invention are used to provide protection from exogenous foreign infectious pathogenic agents (such as bacteria, virus, and the like) prior to expected or possible exposure.
  • the methods and reagents of the invention are used to provide therapeutic effects against exogenous foreign pathogens to which an individual has been exposed or to an individual displaying symptoms of exposure.
  • reagents and methods of the invention are used to treat cancers, including, but not limited to, melanomas, lung cancers, thyroid carcinomas, breast cancers, renal cell carcinomas, squamous cell carcinomas, brain tumors and skin cancers, hi one embodiment, the antigen is a tumor-associated antigen (tumor specific antigen).
  • Tumor antigens are molecules, especially cell surface proteins, that are differentially expressed in tumor cells relative to non-tumor tissues (e.g., telomerase).
  • compositions containing the APC chemotaxins are administered (e.g., in conjunction with antigens) to a subject susceptible to or otherwise at risk of a disease, e.g. a tumor, cancer, infection, and the like.
  • compositions containing the APC chemotaxins are administered (e.g., in conjunction with antigens) to a subject once a disease, e.g. a tumor, cancer, infection, and the like, is detected or diagnosed, or after surgical removal, e.g. of tumors.
  • antigens or vaccine components of the invention include antigens derived from microbial pathogens such as bacteria [e.g., Pertussis (Bordetella pertussis, inactivated whole organism); Cholera (Vibrio cholerae, whole killed organism); Meningitis (Neisseria meningitidis, polysaccharide from organism); Lyme Disease (Borrelia burgdorferi, lipoprotein OspA); Haemophilus B (Haemophilus influenza B polysaccharide, Tetanus conjugate or OmpC); Pneumonia (Streptococcs pneumoniae capsular polysaccharide) Typhoid (Salmonella typhi polysaccharide vaccine, killed whole organism)], viruses including inactivated virus particles, modified live viral particles, and recombinant virus particles to Influenza virus; Hepatitis A; Hepatitis B; Measles; Rubella virus; Mumps ; Rabies; Poliovirus; Japanese
  • the APC chemotaxin, the antigen, or both are delivered as DNA such that the polypeptides are generated in situ.
  • the DNA is "naked," as described, for example, in Ulmer et al, Science 259:1745-1749, 1993 and reviewed by Cohen, 1993 , Science 259:1691-1692.
  • the uptake of naked DNA may be increased by coating the DNA onto a carrier, e.g. biodegradable beads, which is efficiently transported into the cells.
  • the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems.
  • Vectors used to shuttle genetic material from organism to organism, can be divided into two general classes: Cloning vectors are replicating plasmid or phage with regions that are non-essential for propagation in an appropriate host cell, and into which foreign DNA can be inserted; the foreign DNA is replicated and propagated as if it were a component of the vector.
  • An expression vector (such as a plasmid, yeast, or animal virus genome) is used to introduce foreign genetic material into a host cell or tissue in order to transcribe and translate the foreign DNA, such as APC chemotaxin.
  • the introduced DNA is operably-linked to elements, such as promoters, that signal to the host cell to transcribe the inserted DNA.
  • Some promoters are exceptionally useful, such as inducible promoters that control gene transcription in response to specific factors. Operably-linking APC chemotaxin polynucleotide to an inducible promoter can control the expression of APC chemotaxin polypeptide or fragments. Examples of classic inducible promoters include those that are responsive to ⁇ -interferon, heat-shock, heavy metal ions, and steroids such as glucocorticoids (Kaufman, 1990. Methods Enzymol 185: 487-511.) and tetracycline. Other desirable inducible promoters include those that are not endogenous to the cells in which the construct is being introduced, but, however, are responsive in those cells when the induction agent is exogenously supplied.
  • useful expression vectors are often plasmids.
  • other forms of expression vectors such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses) are contemplated.
  • Vector choice is dictated by the organism or cells being used and the desired fate of the vector.
  • Vectors may replicate once in the target cells, or may be "suicide" vectors.
  • vectors comprise signal sequences, origins of replication, marker genes, enhancer elements, promoters, and transcription termination sequences.
  • the compositions can contain one or more antigens (or antigen-encoding polynucleotides).
  • the antigens can be administered in combination with the APC chemotaxin (i.e., in the same mixture). Alternatively, they can be administered separately.
  • the invention provides an immunization method in which a combination of one or more antigens (or antigen-encoding polynucleotides) and one or more APC chemotaxins of the invention (or APC chemotaxin-encoding polynucleotides) are administered to a subject.
  • the antigen or APC chemotaxin is administered in a delivery vehicle such as a physiologically acceptable excipient.
  • an antigen is administered simultaneously with the chemotactic composition
  • the antigen and the chemotactic composition are administered at different times, typically to the same site.
  • the chemotactic composition (without the antigen) can be administered between about 15 m and about 96 h prior to the administration of the antigen, more often between about 15 m and about 48 h, more often between 24 h and 96 h, often between about 48 h and 72 h or between 72 h and 96 h prior to the administration of the antigen.
  • the injections are within 2 cm of each other, preferably within 1 cm or within 0.5 cm of each other on the two dimensional surface of the body.
  • the administrations should also be done to a similar depth and to the same tissue layer (i.e. both injections should be subcutaneous or both intradermal).
  • the depth should be more precisely monitored to achieve a three dimensional equivalent placement of the APC chemotaxin and the antigen to within 2 cm of each other, preferably to within 1 cm, and even better to within 0.5 cm. This is easily accomplished by physicians, nurses and other medically trained personal.
  • the injection site can be marked with an indelible ink to assist the physician.
  • only one dose (administration) of the composition is given, hi another embodiment, the first administration is followed by boosting doses.
  • the APC chemotaxin is administered in multiple doses, often in combination with administration of the antigen (e.g., by co-administration).
  • the APC chemotaxin composition (optionally including antigen) is administered once, twice, three times, or more than three times. The number of doses administered to a subject is dependent upon the antigen, the extent of the disease, and the response of a subject to the chemotactic composition.
  • a suitable number of doses includes any number required to immunize an animal (i.e., to a predetermined antigen).
  • a second administration (booster) of the chemotactic composition and antigen occurs between about 7 days and 1 year after the original administration.
  • a second administration (booster) of the chemotactic composition and antigen occurs between about 14 days and 6 months after the original administration.
  • a second administration (booster) of the chemotactic composition and antigen occurs between about 21 days and 3 months after the original administration, often between about 28 days and 2 months after the original administration
  • third administration occurs between about 14 days and 10 years after the original administration, e.g., between about 14 days and 3 years after the original administration, often between about 21 days and 1 year after the original administration, very often between about 28 days and 6 months after the original administration.
  • boosters maybe administered at 2-week intervals, or 1 month, 3 month or 6 month to 10-year intervals.
  • the amount of APC chemotaxin and antigen will be administered to the subject that is sufficient to immunize an animal against an antigen (i.e., an "immunologically effective dose” or a “therapeutically effective dose”).
  • an amount adequate to accomplish an "immunologically effective dose” will depend on, e.g., the APC chemotaxin and antigen composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician.
  • the effective dose of antigen and APC chemotaxin can be formulated in animal models to achieve an induction of an immune response using techniques that are well known in the art.
  • One having ordinary skill in the art can readily optimize administration to humans based on animal data.
  • the APC chemotaxin is a protein, such as a chemokine
  • a dose will typically be between about 1 fg and about 100 ⁇ g, often between about 1 pg and about 100 ⁇ g, more often between about 1 ng and about 50 ⁇ g, and usually between about 100 ng and about 50 ⁇ g.
  • the dose is between about 1 fg and about 100 ⁇ g per kg subject body weight, often between about 1 pg and about 100 ⁇ g, more often between about 1 ng and about 50 ⁇ g, and usually between about 100 ng and about 50 ⁇ g per kg subject body weight.
  • a chemotactic composition of the present invention contains one or more antigens and one or more chemotaxins at a molar or weight ratio of about 1 : 1000 or greater, chemotaxin to antigen.
  • the ratio of chemotaxin to antigen in the composition is between about 1:10 and 1 : 1000.
  • the ratio of antigen to chemotaxin in the composition is between about 1:10 and 1:1000, or greater than 1:1000 or greater.
  • the ratio of antigen to chemotaxin in the composition is between about 1:10 and 10:1.
  • the APC chemotaxin-containing compositions of the invention may be administered in a variety of ways, as described herein.
  • the chemotactic composition includes carriers and excipients (including but not limited to buffers, carbohydrates, marmitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents, suspending agents, thickening agents and/or preservatives), water, oils, saline solutions, aqueous dextrose and glycerol solutions, other pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents and the like, and/or a conventional adjuvant (e.g., as discussed supra).
  • carriers and excipients including but not limited to buffers, carbohydrates, marmitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents, suspending agents, thickening agents and/or preservative
  • compositions of this invention may be sterilized by conventional, well- known sterilization techniques, or may be sterile filtered.
  • the resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.
  • the APC chemotaxin composition of the invention may be administered in a variety of ways, including by injection (e.g. , intradermal, subcutaneous, intramuscular, intraperitoneal and the like), by inhalation, by topical administration, by suppository, using a transdermal patch, orally.
  • the chemotaxin(s) maybe formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological saline buffer.
  • the solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the chemotactic composition may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the chemotaxin(s) When administration is by inhalation, the chemotaxin(s) may be delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the proteins and a suitable powder base such as lactose or starch.
  • the chemotactic composition When administration is by topical administration, the chemotactic composition may be formulated as solutions, gels, ointments, creams, suspensions, and the like, as are well known in the art. In some embodiments, administration is by means of a transdermal patch.
  • compositions When administration is by suppository (e.g., rectal or vaginal), compositions may also be formulated in compositions containing conventional suppository bases.
  • a composition can be readily formulated by combining the chemotaxin with pharmaceutically acceptable carriers well known in the art.
  • a solid carrier such as mannitol, lactose, magnesium stearate, and the like may be employed; such carriers enable the chemotaxin to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
  • suitable excipients include fillers such as sugars, cellulose preparation, granulating agents, and binding agents.
  • Nucleic acid molecules such as those encoding APC chemotaxins, can be inserted into vectors and used as gene therapy vectors.
  • Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (Nabel et al., US Patent No. 5,328,470 1994. USA ), or by stereotactic injection (Chen et al., 1994. Proc Natl Acad Sci U S A 91 : 3054-7.).
  • the pharmaceutical preparation of a gene therapy vector can include an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
  • the pharmaceutical preparation can include one or more cells that produce the gene delivery system.
  • sustained-release formulations include, for example, APC chemotaxin molecules, allow for the release of APC chemotaxin over extended periods of time, such that without the sustained release formulation, the APC chemotaxin would be cleared from a subject's system, and/or degraded by, for example, proteases and simple hydrolysis.
  • polyclonal and monoclonal antibodies including binding fragments (e.g., F(ab) ) and single chain versions, are well known to those of skill in the art. See, e.g., Coligan, 1991, Current Protocols in Immunology, Wiley/Greene, NY; and Harlow and Lane, 1989, Antibodies: A Laboratory Manual, Cold Spring Harbor Press, NY.
  • a composition comprising a chemotaxin of the invention and an antigen is administered to an animal as described herein, thus inducing or enhancing the immune response in the animal.
  • Polyclonal or monoclonal antibodies are subsequently prepared by standard techniques.
  • compositions of the invention are administered to a subject to stimulate the innate immune response.
  • the innate immune response is body's initial defense against pathogens and is elicited by a variety of cells including APCs (dendritic cells and the macrophages). These cells express surface and cytoplasmic receptors that recognize molecules of foreign origin (e.g., bacterial and viral nucleic acids, proteins, carbohydrates).
  • the dendritic cells and macrophage Upon detecting these signals, the dendritic cells and macrophage elicit a defensive response that includes the release of cytokines (including interferons, TNFalpha, and ELI 2) and chemokines that attract cells such as immature dendritic cells, macrophage, NK cells, and granulocytes, to the site of challenge.
  • cytokines including interferons, TNFalpha, and ELI 2
  • chemokines that attract cells such as immature dendritic cells, macrophage, NK cells, and granulocytes
  • compositions of the invention are useful, not only to attract dendritic cells and other cells to the site of administration, but also that the compositions act to stimulate these cells into eliciting elements of the innate immune response to confer non-specific protection while the body is generating the adaptive response.
  • a composition of the invention is administered (without antigen) prior or post exposure of an anticipated infection.
  • the chemokine is administered with "foreign" molecules (e.g., bacterial or viral nucleic acids, proteins, carbohydrates, or synthetic elements which mimic these elements).
  • kits containing one of more of the following in a package or container: (1) a chemotactic composition of the invention; (2) a pharmaceutically acceptable adjuvant or excipient; (3) and antigen (e.g., a biologically pure antigen); (4) instructions for administration.
  • a chemotactic composition of the invention e.g., a pharmaceutically acceptable adjuvant or excipient
  • antigen e.g., a biologically pure antigen
  • kits containing one of more of the following in a package or container: (1) a chemotactic composition of the invention; (2) a pharmaceutically acceptable adjuvant or excipient; (3) and antigen (e.g., a biologically pure antigen); (4) instructions for administration.
  • antigen e.g., a biologically pure antigen
  • the different components of the composition maybe packaged in separate containers and admixed immediately before use. Such packaging of the components separately may permit long-term storage without losing the active components' functions.
  • the reagents included in the kits can be supplied in containers of any sort such that the life of the different components are preserved and are not adsorbed or altered by the materials of the container.
  • sealed glass ampules may contain lyophilized APC chemotaxin polypeptide or polynucleotide, or buffers that have been packaged under a neutral, non-reacting gas, such as nitrogen.
  • Ampules may consist of any suitable material, such as glass, organic polymers, such as polycarbonate, polystyrene, etc., ceramic, metal or any other material typically employed to hold reagents.
  • suitable containers include simple bottles that may be fabricated from similar substances as ampules, and envelopes, that may consist of foil-lined interiors, such as aluminum or an alloy.
  • Other containers include test tubes, vials, flasks, bottles, syringes, or the like.
  • Containers may have a sterile access port, such as a bottle having a stopper that can be pierced by a hypodermic injection needle.
  • Other containers may have two compartments that are separated by a readily removable membrane that upon removal permits the components to mix. Removable membranes may be glass, plastic, rubber, etc.
  • Kits may also be supplied with instructional materials. Instructions may be printed on paper or other substrate, and/or may be supplied as an electronic-readable medium, such as a floppy disc, CD-ROM, DVD-ROM, Zip disc, videotape, audiotape, etc. Detailed instructions may not be physically associated with the kit; instead, a user may be directed to an internet web site specified by the manufacturer or distributor of the kit, or supplied as electronic mail.
  • Murine monocyte chemoattractant protein (MCP)-5 a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med. 1997 Jan 6;185(1):99-109.
  • TECK a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity. 1997 Aug;7(2):291-301
  • a macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines, Proc Natl Acad Sci U S A 1990 Jul;87(14):5238-42.
  • Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein- 1 and interleukin-6. Nat Med. 1997 Mar;3(3):287-92
  • leukotactin-1 a novel human beta-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J Immunol. 1997 Dec l;159(ll):5201-5
  • MCP-4 Monocyte chemotactic protein 4
  • accession no. P10147 accession no. P10855 (mMIP-l ⁇ ), accession no. P13501 (hRANTES), accession no. P30882 (mRANTES), accession no. Q16627 (hHCC-1), accession no. P55773 (hMPIF-1), accession no. Q16663 (hMIP-l ⁇ ), accession no. Q99616 (hMCP-4), accession no. Q62401 (mMCP-5), accession no. Q03366 (mMARC), accession no. P48298 (mEotaxin), accession no. P10148 (mMCP-l(JE)), accession no.
  • Chemotaxis assays are carried out using purified cells and a 96-well chemotaxis microchamber (ChemoTx ® , NeuroProbes, hie, Gaithersbr ⁇ g MD). hi this assay, a porous polycarbonate filter is used to allow formation of chemoattractant concentration gradient across the filter, as well as to allow cells to migration into the filter or through into the lower well.
  • Migration is allowed to proceed for 90 minutes at 37°C in a tissue culture incubator. Migration is terminated by removing non- migrating cells on the top of the filter using a rubber scrapper.
  • the filter is removed from the apparatus and rinsed with DPBS. (The lower chamber is inspected microscopically to detemiine if any cells have migrated into the wells. If significant number of cells are present in the wells, quantification is done in the wells as well as the filter.)
  • the filter After being removed from the apparatus and rinsed with DPBS (Hyclone), and stained with a cell staining solution such as the Hema3 staining kit (Fisher Scientific).
  • the filter is immersed into the three separate solutions sequentially, each for approximately 5 seconds. After the last solution, the filter is rinsed in water several times. The filter is allowed to air dry and the signal is determined by reading the filter on a plate reader (Molecular Devices) at wavelength 540 run. The magnitude of migration is calculated as the ratio of absorbance between the wells with chemoattractants and the wells with chemotaxis buffer alone.
  • Chemokine Injection h to Mice This example describes an in vivo assay in which the ability of several chemokines to attract dendritic cells is demonstrated.
  • chemokines were obtained from R&D Systems (Minneapolis, MN): MCP2, MCP3, MlPl ⁇ , MIP3 ⁇ , MIP3 ⁇ , RANTES, mMIG, mMDC, mClO, vMIPl.
  • MCP2, MCP3, MlPl ⁇ , MIP3 ⁇ , MIP3 ⁇ , RANTES, mMIG, mMDC, mClO, vMIPl Each chemokine (2 ⁇ g in PBS) was injected intradermally into a different BALB/c mouse.
  • One mouse received a control injection of PBS with no chemokine. Seventy-two hours after injection, the mice were euthanized and the area around the injection site was excised and subjected to immunohistology.
  • chemokines elicited a DEC-205+ (dendritic cell) infiltration to the site of injection after 72 hours when injected intradermally into the mouse.
  • DEC-205+ dendritic cell
  • Mff 3 ⁇ MCP3, Mff 3 ⁇ , mMIG, mMDC, mClO, and viral MIPl showed DC infiltration, with MCP3, mMDC, and mClO showing the best infiltration.
  • a section of the prepared tissue was hematoxalin and eosin stained, and mononuclear cells identified based on cellular morphology (e.g. being mononuclear in contrast to polynuclear).
  • GM-CSF 200 ⁇ g doses
  • RANTES 20 ⁇ g doses
  • RANTES, mMIG, mMDC, mClO, and viral MIPl showed mononuclear infiltration, with mMDC, mClO, and viral MIPl showing the highest level of infiltration. In general, greater infiltration was apparent after 72 hours than after 96 hours. Table 5
  • Mononuclear cell infiltration in the dermis was scored based on a scale of 0 to 4, as follows: 0, no infiltration; 1, slight infiltration; 2, moderate infiltration; 3, substantial infiltration; 4, severe infiltration.
  • chemokines mClO and vMCK-2 caused substantial mononuclear cell infiltration, especially at the 24 hour time-point. It was notable that a chemokine encoded by a mouse virus (vMCK-2) exhibited potent activity in primate cells. Infiltrating cells were observed predominantly in the adipose tissue, although cells were also noted in the subcutaneous region and, in the case of vMCK-2 at 48 hours, in the collagen matrix of the superficial dermis. Chemokines mMDC and vMIP-1 caused less inflammation than mClO and vMCK-2. Table 6
  • samples from the last two monkey studies were analyzed by immunohistochemistry, using antibodies specific for different cell types. These antibodies included: CD68 (expressed on macrophages, neutrophils and dendritic cells), MHC II (antigen- presenting cells, e.g. macrophages and dendritic cells), HAM-56 (macrophages), fascin (dendritic cells, endothelial cells and epithelial cells), elastase (neutrophils), cytokeratin (epithelial cells), CD3 (T cells), CD20 (B cells), and CD la (Langerhans cells).
  • CD68 expressed on macrophages, neutrophils and dendritic cells
  • MHC II antigen- presenting cells, e.g. macrophages and dendritic cells
  • HAM-56 macrophages
  • fascin dendritic cells, endothelial cells and epithelial cells
  • elastase neurotrophils
  • cytokeratin epikerat
  • the vMCK-2-injected skin samples contained primarily neutrophils and antigen-presenting cells, including macrophages and dendritic cells.
  • the mClO- injected skin samples contained primarily antigen-presenting cells, including macrophages and dendritic cells, but few neutrophils.
  • the vMIP-1 -injected skin samples contained primarily neutrophils and macrophages, with few dendritic cells. Few T cells, and no B cells, were found in the skin samples for each of the three chemokines.
  • chemokines mClO and vMCK-2 were found to recruit antigen- presenting cells, including dendritic cells, to the site of injection, these two chemokines were tested for their ability to act as an immunization adjuvant bu augmenting the immune response to a co-injected foreign antigen.
  • OVA incomplete Freund's adjuvant
  • the third group contained OVA plus IFA plus vMCK-2, while the fourth group contained OVA plus IFA plus mClO.
  • the fifth group contained OVA plus vMCK-2, without IFA. Injections were done intradermally in a lOOul volume containing 2mg OVA and 16 ⁇ g chemokine. 10ml of peripheral blood was drawn from each monkey twice a week for three weeks, then subjected to centrifugation over Ficoll to remove the erythrocytes and granulocytes. The plasma supernatant was analyzed by sandwich ELISA to determine the levels of anti-OVA antibodies, using OVA-coated plastic dishes and a biotinylated anti-monkey IgG detection antibody (Table 8).
  • Numbers represent the levels of OVA-specific IgG, expressed in Units/ml, in the plasma of the 15 monkeys. Each horizontal line shows the response of an individual monkey over time after immunization.
  • dilutions of each plasma sample were analyzed by sandwich ELISA, using OVA- coated plates together with a biotinylated anti-monkey IgG detection antibody.
  • Optical densities were converted into arbitrary Units, where a Unit is defined as the inverse of the plasma dilution that produces 50% of the maximum response from a standard curve obtained by serial dilution of an ascites collected from OVA injected mice and containing OVA-specific antibodies.
  • the monkeys injected with OVA + IFA developed a significant antibody response to OVA, as demonstrated by development of circulating anti-OVA IgG, commencing day 12.
  • the levels of OVA-specific IgG in the monkeys injected with OVA, mCl 0 and IFA were substantially greater than those in monkeys not receiving mClO.
  • the inclusion of mClO lead to approximately 4-fold more OVA-specific IgG on day 12, and 3-fold more OVA- specific IgG on both days 16 and 19 compared to monkeys injected with just OVA + IFA alone.
  • vMCK-2 While less potent than mClO, vMCK-2 also exhibited the capacity to augment the OVA-specific antibody response.
  • Example 7 This example describes a procedure to evaluate the efficacy of APC chemotaxins in augmenting systemic and/or mucosal immune responses to infectious diseases.
  • mice are injected either sub-cutaneously, intra-dermally, intra- nasally, or by any other mode with varying doses of the virus, bacterium, or parasite under study, using a typical immunization schedule e.g. days 0, 7, and 14, in the presence or absence of APC chemotaxin given simultaneously with the microorganism in an appropriate formulation.
  • Serum and/or mucosal secretions are collected on days -7, 0, 7, 14, 21, 28 and 35 for antigen-specific antibody analysis by ELISA.
  • Mice are sacrificed at different time intervals after the last immunization to quantitate the antigen-specific antibody-forming cells and antigen-specific T cell responses (both cytotoxic and helper T cell populations) present in immune compartments, using standard procedures.
  • This example describes a procedure to evaluate the efficacy of APC chemotaxins to augment anti-tumor immunity in cancer immunotherapy regimens.
  • mice While many tumor cells express unique tumor-associated antigens, these antigens are invariably weak immunogens and fail to generate potent anti-tumor immunity during tumor progression.
  • APC chemotaxins to augment protective anti-tumor immunity can be evaluated using a model system of cancer immunotherapy in mice.
  • mice are transplanted with a syngeneic thymoma (EL4 cells) that have previously been transfected with the experimental protein antigen OVA. Without further intervention, the tumor grows and eventually kills the mouse. Animals can be at least partially protected by vaccinating them with OVA plus adjuvant to induce an antigen-specific immune response directed against the OVA-transfected thymoma cells.
  • This model is an effective way to evaluate the relative efficacy of adjuvants in augmenting protective anti-tumor immunity.
  • Positive controls in this model include the following adjuvants: CFA, IFA, alum, GM-CSF.
  • the ability of APC chemotaxins to augment cancer immunotherapy regimens can be evaluated by comparison to these known adjuvants.
  • Hybrikines are chimeric chemokine polypeptides designed to generate novel molecules with the appropriate, desired, and enhanced qualities. Usually, the amino acid sequence of a desired hybrikines is determined, and the molecule is produced by chemical synthesis, hi this example, the sequences of chemokines hMCP-2, mClO and mMDC were conceptually divided into functional domains based on the spacing of the invariant cysteine residues. Chimeric sequences were prepared by swapping domains between these molecules. The amino termini region (all amino acids of the mature native protein amino terminal of the first conserved cysteine residue) were swapped onto the remaining portion of a different chemokine molecule to create hybrids. As shown in Fig.
  • the amino terminal regions between mClO and hMCP-2 to create two novel molecules the mC10/hMCP2 and hMCP2/mC10 "hybridkine” molecules.
  • the amino terminal regions between mMDC and hMCP-2 are swapped to create an additional two novel molecules: the mMDC/hMCP2 and l ⁇ MCP2/rnMDC "hybrikine” molecules.
  • These polypeptides were synthesized chemically using classical Fmoc peptide chemistry. The polypeptides are used in in vitro and in vivo chemotaxis assays to determine their chemotactic properties.
  • the present invention provides novel methods and materials relating to APC- chemotactic compositions and therapeutic and prophylactic immunization. While specific examples have been provided, the above description is illustrative and not restrictive. Many variations of the invention will become apparent to those of skill in the art upon review of this specification. The scope of the invention should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope of equivalents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Procédé servant à induire une réponse immune par administration d'une composition contenant un antigène et une chimiotaxine cellulaire présentant un antigène (APC) ou une cellule exprimant une chimiotaxine cellulaire présentant un antigène. Cette chimiotaxine APC est chimiotactique pour des cellules dendritiques. On a exécuté des essais chimiotactiques in vitro et in vivo avec MCP2, MCP3, MIP1b, MIP3a, MIP3beta, RANTES, mMIG, mMDC, mC10, vMIP1. On a constaté une augmentation de la réponse des anticorps lorsqu'on a vacciné des singes avec ovalbumine et mC10 ou vMCK-2.
PCT/US2001/042852 2001-10-24 2001-10-24 Procedes et compositions servant a induire une reponse immune WO2003035106A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2001/042852 WO2003035106A1 (fr) 2001-10-24 2001-10-24 Procedes et compositions servant a induire une reponse immune

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/042852 WO2003035106A1 (fr) 2001-10-24 2001-10-24 Procedes et compositions servant a induire une reponse immune

Publications (1)

Publication Number Publication Date
WO2003035106A1 true WO2003035106A1 (fr) 2003-05-01

Family

ID=21742976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042852 WO2003035106A1 (fr) 2001-10-24 2001-10-24 Procedes et compositions servant a induire une reponse immune

Country Status (1)

Country Link
WO (1) WO2003035106A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028916A1 (fr) * 1993-06-15 1994-12-22 British Biotech Pharmaceuticals Limited Liberation et mobilisation de cellules hematopoïetiques
WO1996036366A1 (fr) * 1995-05-18 1996-11-21 National Jewish Center For Immunology And Respiratory Medicine Therapie genique de regulation de cellules effectrices
CA2256250A1 (fr) * 1997-12-17 1999-06-17 James Lillard Methode pour ameliorer la reaction immunitaire en utilisant des facteurs mitogeniques et chemocinetiques
WO1999029728A1 (fr) * 1997-12-11 1999-06-17 University Of Maryland Biotechnology Institute Procede et composition pour ameliorer l'efficacite d'un vaccin
WO1999043839A1 (fr) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccins, agents d'immunotherapie et procedes pour leur utilisation
EP0974357A1 (fr) * 1998-07-16 2000-01-26 Schering-Plough Chemokines comme adjuvants de la réponse immunitaire
WO2000073432A2 (fr) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation de cellules dendritiques pour accroitre l'immunite
WO2001080887A2 (fr) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Techniques et compositions permettant d'induire une reponse immunitaire
WO2001080882A2 (fr) * 2000-04-21 2001-11-01 Chemocentryx, Inc Methodes et compositions d'induction d'une reponse immunitaire
WO2002040044A2 (fr) * 2000-11-17 2002-05-23 Immunex Corporation Recrutement par chimiotactisme de cellules dendritiques pour renforcer l'immunisation
WO2002058723A2 (fr) * 2001-01-24 2002-08-01 Schering Corporation Chimiokines utilisees comme adjuvants de la reponse immunitaire
WO2002085409A2 (fr) * 2001-04-12 2002-10-31 Chemocentryx Procedes et compositions permettant d'induire une reponse immunitaire

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028916A1 (fr) * 1993-06-15 1994-12-22 British Biotech Pharmaceuticals Limited Liberation et mobilisation de cellules hematopoïetiques
WO1996036366A1 (fr) * 1995-05-18 1996-11-21 National Jewish Center For Immunology And Respiratory Medicine Therapie genique de regulation de cellules effectrices
WO1999029728A1 (fr) * 1997-12-11 1999-06-17 University Of Maryland Biotechnology Institute Procede et composition pour ameliorer l'efficacite d'un vaccin
CA2256250A1 (fr) * 1997-12-17 1999-06-17 James Lillard Methode pour ameliorer la reaction immunitaire en utilisant des facteurs mitogeniques et chemocinetiques
WO1999043839A1 (fr) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccins, agents d'immunotherapie et procedes pour leur utilisation
EP0974357A1 (fr) * 1998-07-16 2000-01-26 Schering-Plough Chemokines comme adjuvants de la réponse immunitaire
WO2000073432A2 (fr) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation de cellules dendritiques pour accroitre l'immunite
WO2001080887A2 (fr) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Techniques et compositions permettant d'induire une reponse immunitaire
WO2001080882A2 (fr) * 2000-04-21 2001-11-01 Chemocentryx, Inc Methodes et compositions d'induction d'une reponse immunitaire
WO2002040044A2 (fr) * 2000-11-17 2002-05-23 Immunex Corporation Recrutement par chimiotactisme de cellules dendritiques pour renforcer l'immunisation
WO2002058723A2 (fr) * 2001-01-24 2002-08-01 Schering Corporation Chimiokines utilisees comme adjuvants de la reponse immunitaire
WO2002085409A2 (fr) * 2001-04-12 2002-10-31 Chemocentryx Procedes et compositions permettant d'induire une reponse immunitaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EO SEONG KUG ET AL: "Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 2, January 2001 (2001-01-01), pages 569 - 578, XP002187584, ISSN: 0022-538X *
NOMURA T ET AL: "ENHANCEMENT OF ANTI-TUMOR IMMUNITY BY TUMOR CELLS TRANSFECTED WITH THE SECONDARY LYMPHOID TISSUE CHEMOKINE EBI-1-LIGAND CHEMOKINE AND STROMAL CELL-DERIVED FACTOR-1ALPHA CHEMOKINE GENES", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 91, 2001, pages 597 - 606, XP002950173, ISSN: 0020-7136 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
US8673299B2 (en) 2007-08-02 2014-03-18 Novimmune S.A. Anti-RANTES antibodies

Similar Documents

Publication Publication Date Title
US7217700B2 (en) Chemokines as adjuvants of immune response
US20190352348A1 (en) Peptides and methods for the treatment of diabetes
CA2434320A1 (fr) Chimiokines utilisees comme adjuvants de la reponse immunitaire
JP2003526315A (ja) アミノ末端修飾を有するケモカイン
AU2002365437B2 (en) Methods and compositions for inducing an immune response
US20020071825A1 (en) Methods and compositions for inducing an immune response
EP1274454B1 (fr) Methodes et compositions d'induction d'une reponse immunitaire
US20030108514A1 (en) Chemokines as adjuvants
US7361329B2 (en) Compositions for inducing an immune response
AU2001257148A1 (en) Methods and compositions for eliciting an immune response
WO2003035106A1 (fr) Procedes et compositions servant a induire une reponse immune
WO2002085409A2 (fr) Procedes et compositions permettant d'induire une reponse immunitaire
US20050234004A1 (en) Compositions and methods of use of W-peptides
JP2000515007A (ja) Ｔ細胞選択的インターロイキン―４アゴニスト
CN112300248B (zh) 一类促进猪机体产生广谱性免疫应答的多肽及其应用
US20040116344A1 (en) Immunomodulatory properties of bip
Singh et al. Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8R interactions
Nukiwa et al. Involvement of Fractalkine/CX3CL1
Flaherty The Kines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载